Hayes Tyrone B, Stuart A Ali, Mendoza Magdalena, Collins Atif, Noriega Nigel, Vonk Aaron, Johnston Gwynne, Liu Roger, Kpodzo Dzifa
Laboratory for Integrative Studies in Amphibian Biology, Group in Endocrinology, Museum of Vertebrate Zoology, Department of Integrative Biology, University of California, Berkeley, California 94720-3140, USA.
Environ Health Perspect. 2006 Apr;114 Suppl 1(Suppl 1):134-41. doi: 10.1289/ehp.8067.
Atrazine is a potent endocrine disruptor that both chemically castrates and feminizes male amphibians. It depletes androgens in adult frogs and reduces androgen-dependent growth of the larynx in developing male larvae. It also disrupts normal gonadal development and feminizes the gonads of developing males. Gonadal malformations induced by atrazine include hermaphrodites and males with multiple testes [single sex polygonadism (SSP)], and effects occur at concentrations as low as 0.1 ppb (microg/L). Here, we describe the frequencies at which these malformations occur and compare them with morphologies induced by the estrogen, 17beta-estradiol (E2) , and the antiandrogen cyproterone acetate, as a first step in testing the hypothesis that the effects of atrazine are a combination of demasculinization and feminization. The various forms of hermaphroditism did not occur in controls. Nonpigmented ovaries, which occurred at relatively high frequencies in atrazine-treated larvae, were found in four individuals out of more than 400 controls examined (1%). Further, we show that several types of gonadal malformations (SSP and three forms of hermaphroditism) are produced by E2 exposure during gonadal differentiation, whereas a final morphology (nonpigmented ovaries) appears to be the result of chemical castration (disruption of androgen synthesis and/or activity) by atrazine. These experimental findings suggest that atrazine-induced gonadal malformations result from the depletion of androgens and production of estrogens, perhaps subsequent to the induction of aromatase by atrazine, a mechanism established in fish, amphibians, reptiles, and mammals (rodents and humans).
阿特拉津是一种强效内分泌干扰物,它会使雄性两栖动物化学去势并雌性化。它会消耗成年青蛙体内的雄激素,并减少发育中的雄性幼虫喉部依赖雄激素的生长。它还会扰乱正常的性腺发育,使发育中的雄性性腺雌性化。阿特拉津诱导的性腺畸形包括雌雄同体和具有多个睾丸的雄性[单性多睾症(SSP)],并且在低至0.1 ppb(微克/升)的浓度下就会产生影响。在此,我们描述这些畸形出现的频率,并将其与雌激素17β-雌二醇(E2)和抗雄激素醋酸环丙孕酮诱导的形态进行比较,作为检验阿特拉津的影响是去雄化和雌性化组合这一假设的第一步。各种形式的雌雄同体在对照组中未出现。在超过400只接受检查的对照组个体中,有4只(1%)出现了在阿特拉津处理的幼虫中相对高频出现的无色素卵巢。此外,我们表明,几种类型的性腺畸形(SSP和三种雌雄同体形式)是由性腺分化期间暴露于E2产生的,而最终形态(无色素卵巢)似乎是阿特拉津化学去势(破坏雄激素合成和/或活性)的结果。这些实验结果表明,阿特拉津诱导的性腺畸形是雄激素耗竭和雌激素产生的结果,这可能是在阿特拉津诱导芳香化酶之后发生的,这一机制在鱼类、两栖动物、爬行动物和哺乳动物(啮齿动物和人类)中已得到证实。